Results 141 to 150 of about 29,030 (239)

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009? [PDF]

, 2019
Background:Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Iezzoni, Lisa I, Kinkel, R Philip, Levin, Jonathan S, Machado, Helene T, Minden, Sarah L, Rosenthal, Meredith B   +5 more
core  

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study

Neurology and Therapy
Introduction The TITAN study examined changes in productivity, ability to work, and quality of life (QoL) before and after treatment with the high-efficacy therapy natalizumab (TYSABRI®) in patients with multiple sclerosis (MS) in France.
Patrick Vermersch, Arnaud Kwiatkowski, Jérôme de Sèze, Alain Créange, Nathalie Texier, Sophie Fantoni-Quinton, Marilyn Gros, Marta Ruiz, Christine Lebrun-Frenay, on behalf of the TITAN Investigators   +9 more
doaj   +1 more source

Inmunología de la Esclerosis Múltiple [PDF]

, 2017
La mediación del sistema inmune en la EM tiene un papel esencial, resaltando las célu-las Th CD4+ y los macrófagos y astrocitos con una expresión anómala de los antígenos CMH II.
Blanco Bravo, María Eugenia
core  

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2018
Background: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the ‘no evidence of disease activity’ (NEDA) definition should now include CLs.
Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki, Lisa Federle, Erica Stropparo, Mariagiulia Anglani, Francesca Rinaldi, Paola Perini, Paolo Gallo   +8 more
doaj   +1 more source

Natalizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

New England Journal of Medicine, 2006
C. Polman, P. W. O'connor, E. Havrdová, M. Hutchinson, L. Kappos, David H. Miller, J. Phillips, F. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. Panzara, A. Sandrock   +13 more
semanticscholar   +1 more source

Use of natalizumab in persons with multiple sclerosis: 2022 update.

Multiple Sclerosis and Related Disorders, 2022
S. Morrow, Fraser Clift, V. Devonshire, E. Lapointe, R. Schneider, M. Stefanelli, R. Vosoughi   +6 more
semanticscholar   +1 more source

Impacto del Natalizumab sobre la población linfocitaria B: un estudio retrospectivo [PDF]

, 2014
La esclerosis múltiple es una compleja enfermedad del Sistema Nervioso Central, caracterizada por una progresiva desmielinizacion del los axones del SNC y de la corteza espinal.
Garonna, Sebastiano
core   +1 more source

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course [PDF]

, 2018
In clinical practice natalizumab is typically used in patients who have experienced breakthrough disease during treatment with interferon beta (IFNβ) or glatiramer acetate.
Hotermans, Christophe, Kappos, Ludwig, O'Connor, Paul, Pace, Amy, Polman, Christopher, Vermersch, Patrick, Wiendl, Heinz, Zhang, Annie   +7 more
core  

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source